Happy Holidays from all of us at Flare Therapeutics! ✨ ❄️ Our team recently gathered to reflect on an incredible year of collaboration, advancement of our discovery programs and lead clinical-stage program FX-909 and a strategic discovery collaboration with Roche. As we wind down for the winter break, we’re filled with gratitude for the accomplishments we’ve made together and look forward to 2025 in which we #BlazeNewPaths!
Flare Therapeutics
Biotechnology Research
Cambridge , MA 6,049 followers
Trailblazing the path to drugging transcription factors to discover precision medicines for cancer & other disease areas
About us
Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines. Flare Therapeutics is lighting up new frontiers in biotech by tackling transcription factors – an elusive protein class long considered “undruggable.” Leveraging our proteomic and mass spectrometry platform, proprietary electrophilic compound library and deep expertise, we are unlocking the potential of these critical proteins to address unmet needs in oncology and beyond. Our lead program, FX-909, is a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that is currently in a Phase I study. We have also advanced a second program with a differentiated mechanism for prostate cancer entering the Investigational New Drug (IND)-enabling stage, alongside a pipeline of earlier-stage programs targeting transcription factors involved in oncology and other therapeutic areas.
- Website
-
http://www.flaretx.com
External link for Flare Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge , MA
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
Get directions
Cambridge , MA, US
Employees at Flare Therapeutics
Updates
-
Our VP of Biochemistry & Chemical Biology Jacob Stuckey, PhD is presenting at American Association for Cancer Research’s Conference on Optimizing Therapeutic Efficacy & Tolerability through Cancer Chemistry today, 12/10 from 2 - 4 pm EST at Plenary Session 4: Drug Design and Optimization - New and emerging targets! Come learn more about our PPARg covalent inverse agonist, FX-909, #FlareTx’s lead candidate for the treatment of bladder cancer. Read more about our science & approach: https://lnkd.in/gRHddDE #biotech #oncology #drugdiscovery
-
-
Our CEO Doug Manion and CFO & President Daphne Karydas will be participating in two conferences in December! Catch them at the 7th Annual Evercore ISI HealthCONx Conference on Dec. 4 or at the Piper Sandler Healthcare Conference on Dec. 5. Let’s connect to talk more about how we’re unlocking the therapeutic potential of transcription factors! https://lnkd.in/efVrGeq6 #biotechnology
-
-
Flare Therapeutics will be in San Francisco during #JPM25 in January! If you’d like to learn more about FlareTx’s approach to drugging transcription factors to discover precision medicines for oncology and other therapeutic areas, please reach out to us. We’d love to connect! #biotech #TranscriptionFactors #drugdiscovery #oncology #flaretx
-
-
We are proud to announce a new collaboration with Roche to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology. We look forward to joining together with unwavering commitment to help more people in their fight against cancer. 🔥 Learn more here: https://lnkd.in/egQCFrP2 #FlareTx #oncology #transcriptionfactors #molecularbiology #biotech #Roche
-
-
This month, find Flare Therapeutics CEO Doug Manion, CFO and President Daphne Karydas and CSO and Co-Founder Robert Sims at the Guggenheim Securities Inaugural Healthcare Innovation Conference and Stifel Financial Corp. 2024 Healthcare Conference. We hope to see you there! https://lnkd.in/dUk7p9dx #biotechnology #flaretx
-
-
Our team is heating up! Join us in welcoming our newest Flares: Peter, Dave, Dawn, Qi, Matt, and Jefferson. We’re thrilled to have them on board as we seek to fully unlock the potential of transcription factors and push for better solutions for patients. Interested in joining us? Explore our current job openings: https://lnkd.in/ePNXz9sF #bringyourflare #team #oneflare #welcome
-
-
In recent weeks, Flare Therapeutics has been showing our team spirit, lacing up our sneakers and walking together for #CanadaWalksforBladderCancer and cheering on our local team, the Red Sox. #flaretx Bladder Cancer Canada
-
-
Today, in recognition of #WorldCancerResearchDay, a day dedicated to raising awareness for cancer research, the team at Flare Therapeutics is restating our commitment to advancing potential new therapies for patients. In targeting transcription factors, we aim to #BlazeNewPaths, in the pursuit of drugging the undruggable. This core value guides our work, and we hope you’ll join us in recognizing the contribution of researchers worldwide, including those at FlareTx! #FlareTx #biotech #WCRD #oncology
-
-
Our Vice President of Medicinal Chemistry Jonathan Wilson represented #FlareTx with a poster presentation at the Gordon Research Conferences over the weekend. We want to acknowledge his significant contributions to FlareTx as we advance the research of drugging transcription factors. #biotech #oncology #medicinalchemistry #drugdiscovery #GordonResearch
-